Where is MiRagen located?

MiRagen is headquartered in Boulder, United States. It is registered at Boulder, Colorado.

How many employees does MiRagen have?

As of Apr 30, 2026, the latest employee count at MiRagen is 354.

Is MiRagen a funded company?

MiRagen is a funded company, having raised a total of $55.7M across 19 funding rounds to date. The company's 1st funding round was a $***** PE round.

When was the latest funding round of MiRagen?

MiRagen's latest funding was a $***** Post IPO round on Oct 28, 2020, with participation from 10 investors. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $1.19B in funding in 2026 to date.

What is the annual revenue of MiRagen?

Annual revenue of MiRagen is between $1M and $10M as on Dec 31, 2019

Where does MiRagen rank among its competitors?

MiRagen ranks 443rd amongst 3708 active competitors, of which 1248 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of MiRagen?

MiRagen's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

MiRagen - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

MiRagen is a developer of microRNA-based therapeutic solutions for treating multiple diseases. The company's pipeline for drug candidates includes MRG-106 used for haematological malignancy, MRG - 107 used for Neurodegeneration, and MRG 110 for Ischemia.

Website: miragen.com
Social
Email ID: *****@miragen.com
Phone Number: +1 **********
Registered Address: Boulder, Colorado

Key Metrics

Founded Year

2007

Location

Boulder, United States

Stage

Public

Total Funding

$55.7M in 19 rounds

Latest Funding Round

Post IPO, Oct 28, 2020, $*****

Investors

Remeditex & 22 more

Ranked

443^rd among 3708 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2019

Employee Count

354 as on Apr 30, 2026

Investment & Acquisitions

Viridian & 1 more

Similar Companies

Jazz Pharmaceuticals & 3516 more

Exit Details

Public

View MiRagen's full profile

MiRagen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MIRAGEN THERAPEUTICS, INC. CIN: 471187261 , United States, Active	Dec 31, 1999	$1M - $10M (As on Dec 31, 2019)	139 (As on Dec 31, 2024)	-

MiRagen got listed on Jun 20, 2014.

Click here to take a look at MiRagen's IPO in detail

MiRagen has raised a total funding of $55.7M over 19 rounds. Its latest funding round was a Post IPO round on Oct 28, 2020 for $*****. 10 investors participated in its latest round. MiRagen has 23 institutional investors.

Here is the list of recent funding rounds of MiRagen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 28, 2020	1899464	Post IPO	4670548	1057266	6040194	8639903
Oct 31, 2019	6732701	Post IPO	4505958	6240126	4161141	5281919
Nov 14, 2017	5983240	Post IPO	5951409	9776311	3995683	7535743

Access funding benchmarks and valuations. Sign up today!

View details of MiRagen's funding rounds and investors

The founders of MiRagen are Bruce Booth, William Marshall and Sanjoy Mahanty.

Here are the details of MiRagen's key team members:

Bruce Booth: Co-Founder & Chairman of MiRagen and founder of 1 other company.
William Marshall: Co-Founder of MiRagen.
Contact Info: 1 email address
Sanjoy Mahanty: Co-Founder of MiRagen.

View details of MiRagen's Founder profiles and Board Members

MiRagen's employee count trend

MiRagen has 354 employees as of Apr 26. Here is MiRagen's employee count trend over the years:

Uncover MiRagen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MiRagen include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of MiRagen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
443rd	MiRagen 2007, Boulder (United States), Public	Developer of microRNA-based therapeutic solutions for treating multiple diseases	$55.7M	BVF Partners, Amgen Business Development ... & 21 others	54/100